Hims & Hers Peptide Treatments.
Courtesy: Him and She
His health and that of him announced Wednesday that it will offer five formulations of peptides and compounded longevity treatments in the United States as part of the initial rollout of its Peptides+ platform, not all of which are approved by regulators.
Even in announcing the new products, Hims & Hers acknowledged that it still has a lot to learn about how best to use peptides and their effectiveness, highlighting the uncertainty surrounding the growth space.
The new offerings come after the federal government eased restrictions on the composition of certain unapproved peptides, which are short chains of amino acids. These products have exploded in popularity among fitness and longevity enthusiasts who attest that they help with muscle growth, rapid injury recovery, and anti-aging, even though most lack evidence from robust human trials.
In late October, Hims launched an early access list for upcoming peptide offerings, and more than 10,000 people signed up in 15 days, a company spokesperson said in a statement.
None of the Company’s specific compounded products are approved by the Food and Drug Administration. But Hims said they are authorized by law and formulated by pharmacies “that adhere to rigorous quality standards and are licensed and inspected by state pharmacy boards.”
Products include formulations comprised of sermorelin, a peptide that stimulates the release of growth hormone and is marketed for recovery, body composition and anti-aging; glutathione, a peptide promoted for anti-aging and sports recovery; and nicotinamide adenine dinucleotide, or NAD+, a coenzyme that plays a role in cellular metabolism.
The company will also offer versions made with vitamin B-12, a vitamin needed to make red blood cells, form DNA and maintain healthy nerve function, and L-carnitine, an amino acid derivative that helps the body turn fat into energy. The FDA has approved certain prescription forms of both peptides for established medical uses, primarily for diagnosed deficiencies of these compounds.
Hims said he plans to add more U.S.-made peptides and therapies over time. This includes BPC-157, an unapproved peptide derived from a protein found in human gastric juice and marketed for healing processes. The company also aims to introduce another unapproved peptide called TB-500, derived from a naturally occurring protein in the body and marketed for broader, systemic soft tissue recovery and flexibility. Most research on both has been done on animals, not humans.
Its Peptides
Source: Health for him and for her
To receive the products, Hims platform members will begin with an assessment of their health history and goals with a licensed provider trained in peptide therapies, who can tailor a personalized plan to their needs, if appropriate.
The company said it intends to use its communications platform to reach out to patients and ensure they get the results they want.
“If that’s not the case, we need to do something,” Dr. Anant Vinjamoori, Hims’ chief medical officer, told CNBC. “We need to, you know, adjust the dose when appropriate, or in some cases consider other compounds that may be more suitable. And of course, there will also be cases where we need to steer people to other care options.”
However, Vinjamoori said there is still uncertainty about how best to use peptides.
“We don’t have all the data that we’re used to with compounds like this,” he said. “We have an opportunity to do it right, and I think we see it as our responsibility, with a company of our size and our skills and our resources, to really lead.”
Vinjamoori added that people with serious illnesses, such as cardiovascular disease, liver disease and kidney disease, will not be candidates for these compounds at this time.
Meanwhile, Andrew Huberman, a well-known neuroscientist, podcaster and professor at Stanford University School of Medicine who recently joined Hims’ board of directors, in a statement called the compounds “real medical treatments, not just a wellness trend.” He said Hims provides safe access through “reliable supply and physician oversight.”
Potential problems with peptides
But health experts have expressed concerns about the broader marketing of peptides in the United States and their access on telehealth platforms.
“With peptides, I think you have to look at them in the same way as any drug that hasn’t been rigorously tested,” said Joshua Kritzer, a chemistry professor at Tufts University. “Without actual testing, you only have anecdotal information, and that’s simply not enough to introduce a substance into your body.”
Kritzer said the lack of large-scale clinical trials means researchers cannot rule out rare and potentially serious complications linked to peptides — the type of risks that have led regulators to reject or pull otherwise effective drugs from the market after undergoing comprehensive human testing.
Without these tests, it’s also unclear how telehealth companies, doctors and pharmacies can make decisions about what doses patients should take, said Paul Knoepfler, professor of cell biology and human anatomy at UC Davis Health. While some people rely on anecdotal data from real peptide users, “the dosing of these products hasn’t really been established,” he added.
Knoepfler said one risk is that injecting too much of a synthetic peptide into patients could trigger “weird immune responses that are really bad for your health” because the body might recognize it as foreign.
“With peptides, it’s very unclear,” Knoepfler told CNBC. “How does one know what would be an effective amount for whatever you’re hoping to do, and what amount would carry more risk?”
But he added that the more contact patients can have with doctors about taking a peptide compound, the better. Providers, including those tied to telehealth companies, should make sure patients are well informed about the possible risks and unknowns of a given product and take into account their preexisting conditions, history of cancer and other medications, Knoepfler said.
This seems to be consistent with the approach taken by Hims & Hers. The company says patients using the peptide and longevity products can also use its Care+ offering, which combines treatment with ongoing support. This includes twice-yearly lab testing to track their progress and the ability to message peptide therapy-trained providers around the clock with any questions.
Him Peptides
Source: Health for him and for her
Still, Kritzer argued that having a doctor who only knows a patient through mail-order platforms or online websites “does not constitute sufficient supervision to prescribe you a prescription drug,” particularly if it is an unapproved drug.
Hims’ ability to legally sell some of these peptides stems from a major change in federal oversight by the Department of Health and Human Services. It issued a policy in October that the Food and Drug Administration will not take enforcement action against licensed pharmacies, federal facilities or physicians who prepare and distribute six unapproved peptides while the formal rules are revised.
In practice, this means that these pharmacies and other companies can now carry them, even though peptides are not yet on the FDA’s official list of ingredients that pharmacies are allowed to make. This does not translate into formal approval of specific peptides.
This policy followed a 2023 decision by the Biden administration that the FDA banned compounding pharmacies from producing popular peptide formulations due to safety concerns, impurities and immune reactions.
HHS Secretary Robert F. Kennedy Jr. has supported broader access to peptides, calling himself a “big fan” of the treatments and arguing that the restrictions were pushing Americans to turn to potentially dangerous products from abroad. Kennedy previously described using BPC-157 to treat muscle injury.
This announcement also comes after Hims acquired a California-based peptide manufacturing facility in February 2025 equipped with advanced peptide synthesizers.
The proof – or lack thereof
Evidence for the effectiveness of peptides varies depending on the compound.
A 2026 systematic review examining 113 studies, including both small human trials and rodent research, found no eligible clinical trials proving that IV or intramuscular administration of NAD+ improves anti-aging, energy, or wellness parameters in humans.
There is evidence of specific uses of certain peptides, such as potential weight loss. A review of 37 trials of L-carnitine found that participants lost about 2.7 pounds on average, although this analysis does not demonstrate that a compounded injection works in the same way.
Meanwhile, vitamin B-12 injections are most often used to help people with a diagnosed deficiency rather than for preventative care. American survey data shows that only 3.6% of adults suffer from vitamin B-12 deficiency.
The evidence for glutathione is also slim. IV injections are widely marketed for skin whitening, but are not approved by the FDA for this purpose.
A small study published in the Journal of Pakistan Association of Dermatologists evaluating IV glutathione showed that the treatment is “not very effective” in lightening skin and loses effectiveness over time.
The FDA also said in August that it had received reports of at least 30 patients experiencing adverse reactions after receiving compounded IV glutathione alone or in combination with other ingredients from different compounding pharmacies.
All of the glutathione linked to the reports came from the same wholesale distributor and was labeled as a dietary supplement, which is not a suitable ingredient for making injectable medications. Two of Texas’ pharmacies have issued recalls related to high levels of endotoxin in their injectable glutathione medications.
These studies and reports don’t specify how Hims’ exact combination will work, but they highlight current limitations in the data studying the treatments and the questions surrounding them.
Gn bussni
